Mesoblast Ltd (ASX:MSB) is a leader in providing allogeneic (off the shelf) cellular medicines. It owns a portfolio of late-stage product candidates with three product candidates in Phase 3 trials, being acute graft versus host disease, chronic heart failure and chronic low back pain due to degenerative disc disease. The company has facilities in Melbourne, New York, Singapore and Texas and is listed on the ASX and the NASDAQ.
Here are the headlines from the S&P/ASX 200 (INDEXASX:XJO)(ASX:XJO) and Australian finance circles on Wednesday morning, with the USA’s Federal Reserve signalling higher rates to come.
There is no doubt that Atlassian Corporation PLC (NASDAQ:TEAM), Australia’s darling IT company, is now a global success.
